**Introduction**

HPLC is the method of choice for dissolution and assay testing of norethindrone/mestranol tablets. A cyano column (USP-L10) is specified in the dissolution method for norethindrone/mestranol tablets published in the USP Formulary (USP 27 - NF 22) [1]. Although a C8 column (USP-L7) is specified for the assay analysis for norethindrone/mestranol tablets in the same publication, the results presented below indicate that the L10 column may provide the optimal separation for both analyses.

**Experimental**

All separations were performed isocratically at 1 mL/min and 25 °C, with the eluent compositions specified in Figure 1. An Agilent 1100 HPLC system was used, consisting of a binary pump, autosampler, and diode array detector (DAD). Organic and aqueous solvents were mixed online. Detection was at 205 nm. Five-microliter injections were made with the autosampler. The HPLC columns are specified in the figures.

Steroid standards were purchased from Sigma, Inc. and dissolved in the eluent corresponding to each column. Sample concentrations were 0.514 µg/µL (norethindrone), 0.407 µg/µL (progesterone), and 0.057 µg/µL (mestranol).

**Results and Discussion**

Figure 1 shows the separation of norethindrone, progesterone [internal standard (ISTD) for USP assay method], and mestranol on the Eclipse XDB-CN (Figure 1A) and Eclipse XDB-C8 (Figure 1B).
This mixture of steroids is well separated on both columns, including a small impurity eluting after norethindrone, using the elution conditions specified for each column in the USP Formulary (USP 27 - NF 22) for the dissolution (L10 column) and assay (L7 column) of norethindrone/mestranol tablets. Although the dissolution method does not specify the use of an ISTD, the progesterone peak is also well separated on the L10 (Eclipse XDB-CN) column.

Table 1 indicates that the Eclipse XDB-CN (L10-USP) column easily meets these requirements for the dissolution method and that the Eclipse XDB-C8 (L7) column easily meets these requirements for the assay method. The RRT for the mestranol peak on the Eclipse XDB-C8 column actually exceeds the requirement specified in the assay method but this simply indicates greater selectivity and higher resolution on the Eclipse XDB-C8 column.
Table 1. USP Performance Measures for Norethindrone/Mestranol Methods

<table>
<thead>
<tr>
<th>Column</th>
<th>Steroid</th>
<th>N</th>
<th>Tf</th>
<th>RRT</th>
<th>RRT</th>
<th>Rs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eclipse XDB-CN (L10)</td>
<td>Norethindrone</td>
<td>10,200</td>
<td>1.09</td>
<td>0.41</td>
<td>1.00</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Progesterone</td>
<td>12,100</td>
<td>1.08</td>
<td>0.65</td>
<td>1.59</td>
<td>12.2</td>
</tr>
<tr>
<td></td>
<td>Mestranol</td>
<td>12,300</td>
<td>1.08</td>
<td>1.00</td>
<td>2.45</td>
<td>11.7</td>
</tr>
<tr>
<td>Eclipse XDB-C8 (L7)</td>
<td>Norethindrone</td>
<td>11,100</td>
<td>1.06</td>
<td>1.00</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Progesterone</td>
<td>12,800</td>
<td>1.04</td>
<td>2.36</td>
<td>–</td>
<td>22.3</td>
</tr>
<tr>
<td></td>
<td>Mestranol</td>
<td>12,300</td>
<td>1.00</td>
<td>3.36</td>
<td>–</td>
<td>9.8</td>
</tr>
</tbody>
</table>

The chromatograms in Figure 1 and data in Table 1 also suggest that the Eclipse XDB-CN might be suitable for both dissolution and assay methods. It easily meets the requirements for both methods and has the advantages of a shorter analysis time (33% shorter), with subsequent lower solvent consumption per analysis, as well as using a lower percentage of acetonitrile, which is also a cost savings.

**Conclusions**

The Eclipse XDB-CN (L10) and Eclipse XDB-C8 (L7) columns meet or exceed all the performance requirements for the USP methods for dissolution and assay, respectively, of norethindrone/mestranol tablets. In addition, the results for the Eclipse XDB-CN column suggest that it might be suitable for both the dissolution and assay methods, which would result in a faster (33%), and lower cost assay method.

**Reference**

1. USP Method "Norethindrone and Mestranol Tablets", USP27 - NF22.
For More Information

For more information on our products and services, visit our Web site at www.agilent.com/chem.

The author, William E. Barber, Ph.D. (LC Applications Specialist) is based at Agilent Technologies, Wilmington, Delaware.

Agilent shall not be liable for errors contained herein or for incidental or consequential damages in connection with the furnishing, performance, or use of this material.

Information, descriptions, and specifications in this publication are subject to change without notice.

© Agilent Technologies, Inc. 2004

Printed in the USA
May 5, 2004
5989-1043EN

www.agilent.com/chem